Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Kim, Jeong Kook ^a   Kim, Joon Young ^b,c   Kim, Han Jong ^b,d   Park, Keun Gyu ^b   Harris, Robert A ^e   Cho, Won Jea ^d   Lee, Jae Tae ^b   Lee, In Kyu ^b  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d Chonnam National University   (South Korea)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; ARTEMISIA; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; CYCLIN D1; G1 PHASE; HCT116 CELLS; HELA CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-6; JANUS KINASE 2; MALE; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84894219342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080391     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Sternberg CN (2011) Novel treatments for castration-resistant prostate cancer. Eur J Cancer 47: S195-S199. doi:10.1016/S0959-8049(11)70980-7. PubMed: 21943975.
3. Sartor AO (2011) Progression of metastatic castrate-resistant prostate cancer: Impact of therapeutic intervention in the post-docetaxel space. Hematol Oncol 4: 18. doi:10.1186/1756-8722-4-18. PubMed: 21513551.
4. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N et al. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666. PubMed: 12438264. (Pubitemid 35364135)
5. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B et al. (2008) Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172: 1717-1728. doi:10.2353/ajpath.2008.071054. PubMed: 18483213. (Pubitemid 351793362)
6. Darnell JE (1997) STATs and gene regulation. Science 277: 1630-1635. doi:10.1126/science.277.5332.1630. PubMed: 9287210.
7. Zhong Z, Wen Z, Darnell JE (1994) Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98. doi:10.1126/science.8140422. PubMed: 8140422. (Pubitemid 24144493)
8. Bromberg J, Darnell JE (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473. doi:10.1038/sj.onc.1203476. PubMed: 10851045. (Pubitemid 30339202)
9. Yu H, Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4(2): 97-105. doi:10.1038/nrc1275. PubMed: 14964307. (Pubitemid 38198738)
10. Decker T, Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19: 2628-2637. doi:10.1038/sj.onc.1203481. PubMed: 10851062. (Pubitemid 30339219)
11. Wen Z, Zhong Z, Darnell JE (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-250. doi:10.1016/0092-8674(95)90311-9. PubMed: 7543024.
12. Qin HR, Kim HJ, Kim JY, Hurt EM, Klarmann GJ et al. (2008) Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res 68: 7736-7741. doi:10.1158/0008-5472.CAN-08-1125. PubMed: 18829527.
13. Al Zaid Siddiquee K, Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18: 254-267. doi:10.1038/cr.2008.18. PubMed: 18227858. (Pubitemid 351206162)
14. Haftchenary S, Avadisian M, Gunning PT (2011) Inhibiting aberrant Stat3 function with molecular therapeutics: A progress report. Anti Cancer Drugs 22: 115-127. doi:10.1097/CAD.0b013e328341185b. PubMed: 21063201.
15. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115. doi:10.1016/S1074-7613(00)80011-4. PubMed: 10023775. (Pubitemid 29077388)
16. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97: 4227-4232. doi:10.1073/pnas.97.8.4227. PubMed: 10760290. (Pubitemid 30226115)
17. Garcia R, Bowman TL, Niu G, Yu H, Minton S et al. (2001) Constitutive activation of Stat3 by the src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513. doi:10.1038/sj.onc.1204349. PubMed: 11420660. (Pubitemid 32531347)
18. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE (1998) Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18: 2553-2558. PubMed: 9566875. (Pubitemid 28183425)
19. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP et al. (1998) Stat3 activation by src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18: 2545-2552. PubMed: 9566874. (Pubitemid 28183424)
20. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG et al. (1999) Stat3 as an oncogene. Cell 98: 295-303. doi:10.1016/S0092-8674(00)81959-5. PubMed: 10458605. (Pubitemid 29380565)
21. Zhao M, Jiang B, Gao FH (2011) Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 18: 4012-4018. doi:10.2174/092986711796957284. PubMed: 21824090.
22. Fok TF (2001) Neonatal jaundice - traditional chinese medicine approach. J Perinatol 21: S98-100. doi:10.1038/sj.jp.7210643. PubMed: 11803427.
23. Huang W, Zhang J, Moore DD (2004) A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 113: 137-143. doi:10.1172/JCI18385. PubMed: 14702117. (Pubitemid 38541640)
24. Huang HC, Chu SH, Chao PD (1991) Vasorelaxants from chinese herbs, emodin and scoparone, possess immunosuppressive properties. Eur J Pharmacol 198: 211-213. doi:10.1016/0014-2999(91)90624-Y. PubMed: 1830846.
25. Huang HC, Weng YI, Lee CR, Jan TR, Chen YL et al. (1993) Protection by scoparone against the alterations of plasma lipoproteins, vascular morphology and vascular reactivity in hyperlipidaemic diabetic rabbit. Br J Pharmacol 110: 1508-1514. doi:10.1111/j.1476-5381.1993.tb13993.x. PubMed: 8306094.
26. Hoult JR, Payá M (1996) Pharmacological and biochemical actions of simple coumarins: Natural products with therapeutic potential. Gen Pharmacol 27: 713-722. doi:10.1016/0306-3623(95)02112-4. PubMed: 8853310. (Pubitemid 26233347)
27. Lee YM, Hsiao G, Chang JW, Sheu JR, Yen MH (2003) Scoparone inhibits tissuefactor expression in lipopolysaccharide-activated human umbilical vein endothelial cells. J Biomed Sci 10: 518-525. doi:10.1007/BF02256113. PubMed: 12928592. (Pubitemid 37025962)
28. Jang SI, Kim YJ, Kim HJ, Lee JC, Kim HY et al. (2006) Scoparone inhibits PMA-induced IL-8 and MCP-1 production through suppression of NF-kappaB activation in U937 cells. Life Sci 78: 2937-2943. doi:10.1016/j.lfs.2005.11.020. PubMed: 16376386.
29. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ et al. (2009) Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol 29: 1558-1564.
30. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426. doi:10.1038/18884. PubMed: 10201372. (Pubitemid 29180374)
31. Kennell JA, O'Leary EE, Gummow BM, Hammer GD, MacDougald OA (2003) T-cell factor 4N (TCF-4N), a novel isoform of mouse TCF-4, synergizes with beta-catenin to coactivate C/EBPalpha and steroidogenic factor 1 transcription factors. Mol Cell Biol 23: 5366-5375. doi:10.1128/MCB.23.15.5366-5375.2003. PubMed: 12861022. (Pubitemid 36950891)
32. Powell CM, Rudge TL, Zhu Q, Johnson LF, Hansen U (2000) Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. EMBO J 19: 4665-4675. doi:10.1093/emboj/19.17.4665. PubMed: 10970859.
33. Yang SH, Khadka DB, Cho SH, Ju HK, Lee KY et al. (2011) Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. Bioorg Med Chem 19: 968-977. doi:10.1016/j.bmc.2010.11.057. PubMed: 21185195.
34. Becker S, Groner B, Müller CW (1998) Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394: 145-151. doi:10.1038/28101. PubMed: 9671298. (Pubitemid 28325960)
35. Yuan ZL, Guan YJ, Chatterjee D, Chin YE (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue.Science 307: 269-273. doi:10.1126/science.1105166. PubMed: 15653507. (Pubitemid 40116244)
36. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142. doi:10.1172/JCI200215617. PubMed: 11994401.
37. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP (1997) Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res 57: 978-987. PubMed: 9041204. (Pubitemid 27098027)
38. Corcoran NM, Costello AJ (2003) Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 91: 545-553. doi:10.1046/j.1464-410X.2003.04025.x. PubMed: 12656913. (Pubitemid 36570580)
39. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T et al. (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706. PubMed: 10914713. (Pubitemid 30482107)
40. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S et al. (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444. PubMed: 12429632. (Pubitemid 35340719)
41. Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 102: 4700-4705. doi:10.1073/pnas. 0409894102. PubMed: 15781862. (Pubitemid 40471517)
42. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104: 7391-7396. doi:10.1073/pnas.0609757104. PubMed: 17463090. (Pubitemid 47185916)
43. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ et al. (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69: 193-202. doi:10.1158/0008-5472.CAN-08-2575. PubMed: 19118003.
44. Fletcher S, Turkson J, Gunning PT (2008) Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. Chemmedchem 3: 1159-1168. doi:10.1002/cmdc.200800123. PubMed: 18683176.
45. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477. doi:10.1021/np068054v. PubMed: 17309302. (Pubitemid 46595760)
46. Karikas GA (2010) Anticancer and chemopreventing natural products: Some biochemical and therapeutic aspects. J BUON 15: 627-638. PubMed: 21229622.
47. Gordaliza M (2007) Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776. doi:10.1007/s12094-007-0138-9. PubMed: 18158980.
48. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M et al. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362. doi:10.1172/JCI9940. PubMed: 11160159.